Evidence map›Paper›PMID 34203685›Full record

ArticleBiosensors2021

Development of a Diagnostic Biosensor Method of Hypersensitivity Pneumonitis towards a Point-of-Care Biosensor.

Tatiana Fiordelisio, Ivette Buendia-Roldan, Mathieu Hautefeuille, Diana Del-Rio, Diana G Ríos-López, Diego Zamarrón-Hernández, Samuel Amat-Shapiro, Andrea Campa-Higareda, Edgar Jiménez-Díaz, Erika González-Villa and 7 more

Abstract read
In one paragraph

Article in Biosensors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. New detection method of SARS-CoV-2 antibodies toward a point-of-care biosensor.Frontiers in bioengineering and biotechnology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tatiana FiordelisioDepartamento de Biología, Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0002-9282-1476
Ivette Buendia-RoldanInstituto Nacional de Enfermedades Respiratorias Dr. Ismael Cosio Villegas, Mexico City 14080, Mexico.ORCID 0000-0002-2825-506X
Mathieu HautefeuilleLaboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia LANSBioDyT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0003-3918-0320
Diana Del-RioDepartamento de Biología, Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0002-7587-0866
Diana G Ríos-LópezLaboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia LANSBioDyT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0001-5533-4399
Diego Zamarrón-HernándezLaboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia LANSBioDyT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0002-8315-5504
Samuel Amat-ShapiroLaboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia LANSBioDyT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Andrea Campa-HigaredaLaboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia LANSBioDyT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Edgar Jiménez-DíazDepartamento de Biología, Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0002-7456-6010
Erika González-VillaLaboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia LANSBioDyT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Janikua Nelson-MoraLaboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia LANSBioDyT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Natllely García-CarreñoLaboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia LANSBioDyT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Jehú López-AparicioLaboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia LANSBioDyT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0003-4433-9092
Eduardo MontesInstituto Nacional de Enfermedades Respiratorias Dr. Ismael Cosio Villegas, Mexico City 14080, Mexico.
Armando Santiago-RuizInstituto Nacional de Enfermedades Respiratorias Dr. Ismael Cosio Villegas, Mexico City 14080, Mexico.ORCID 0000-0003-2576-9601
Annie PardoDepartamento de Biología, Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Moisés SelmanLaboratorio Nacional de Soluciones Biomiméticas para Diagnóstico y Terapia LANSBioDyT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0002-1022-4783

Funding

CONACyT - FOSISS 289685
6 · The paper itself

Abstract

In spite of a current increasing trend in the development of miniaturized, standalone point-of-care (PoC) biosensing platforms in the literature, the actual implementation of such systems in the field is far from being a reality although deeply needed. In the particular case of the population screenings for local or regional diseases related to specific pathogens, the diagnosis of the presence of specific antibodies could drastically modify therapies and even the organization of public policies. The aim of this work was to develop a fast, cost-effective detection method based on the manipulation of functionalized magnetic beads for an efficient diagnosis of hypersensitivity pneumonitis (HP), looking for the presence of anti-pigeon antigen antibodies (APAA) in a patient's serum. We presented a Diagnostic Biosensor Method (DBM) in detail, with validation by comparison with a traditional high-throughput platform (ELISA assay). We also demonstrated that it was compatible with a microfluidic chip that could be eventually incorporated into a PoC for easy and broad deployment using portable optical detectors. After standardization of the different reaction steps, we constructed and validated a plastic chip that could easily be scaled to high-volume manufacturing in the future. The solution proved comparable to conventional ELISA assays traditionally performed by the clinicians in their laboratory and should be compatible with other antibody detection directly from patient samples.

Indexed as

Alveolitis, Extrinsic AllergicBiosensing TechniquesAntibodiesEnzyme-Linked Immunosorbent AssayEquipment DesignHumansImmunomagnetic SeparationLab-On-A-Chip DevicesMicrofluidicsPoint-of-Care SystemsAntibodiesantibodiesmagnetic beadsPoC

Identifiers

PMID34203685
PMCPMC8232117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.